Regulatory Submissions & Stakeholder Management | RC Training
Regulatory Submissions & Stakeholder Management
Master the IRB submission pipeline at portfolio scale — initial submissions, continuing reviews, amendments, and safety reports flowing through multiple IRBs simultaneously. This course covers multi-IRB navigation, regulatory authority interactions including FDA Form 1572 management and clinical holds, and the stakeholder communication systems that keep submissions moving across every active study at your site.
Studied within the Regulatory Coordinator track. One payment of $179 USD covers all seven courses and the certificate.
Modules
8
Lessons
31
Knowledge checks
8
Study time
~11
about
h
Final exam55 questions · 80% to pass · 75 minutes · up to 3 attemptsICH E6(R3)Intermediate
What you will be able to do
01Manage the complete IRB/IEC submission lifecycle -- from initial application through continuing review and study closure -- across a multi-study portfolio (ICH E6(R3) Annex 1, Sections 1.1-1.5 and 2.4)
02Design submission tracking systems and quality control workflows that prevent missed deadlines, incomplete packages, and IRB lapses across concurrent studies
03Navigate the operational differences between central IRB, local IRB, and reliance agreement models, adapting submission strategies to each structure
04Coordinate stakeholder communications during the submission process, including PI signature collection, sponsor notification requirements, and IRB correspondence management
05Manage FDA Form 1572 updates, financial disclosure obligations (21 CFR 54), and other regulatory authority interactions that arise at the investigator site level
06Execute continuing review processes with the documentation rigor and timeline discipline required to prevent regulatory lapses that would shut down enrollment
Eight modules,one final exam.
Eight modules and thirty-one lessons, each module closing with a knowledge check, and a final exam to complete the course.
3.1Continuing review timelines and the cost of a regulatory lapseRead free
3.2Building the continuing review package: study status, enrollment data, adverse events, and protocol deviations
3.3Managing continuing review across 15+ studies: batching, staggering, and the 60-day rule
3.4Post-approval IRB correspondence: managing stipulations, modifications required, and conditional approvals
IVIRB models and reliance agreements5 lessons · knowledge check
4.1The IRB ecosystem in 2025: central, local, commercial, institutional, and VA
4.2Reliance agreements and the single IRB mandate: what the reviewing IRB does, what the relying institution still requires
4.3Managing multiple IRBs at one site: when different studies use different review structures
4.4Mid-study IRB transitions: managing regulatory documentation and notification requirements
4.5Navigating IRB-specific idiosyncrasies: forms, timelines, reviewer preferences, and unwritten rules
VRegulatory authority interactions at the site level4 lessons · knowledge check1 free lesson
5.1FDA Form 1572: what it commits your investigator to, and when it needs updatingRead free
5.2Financial disclosure requirements under 21 CFR Part 54: the RC's coordination role
5.3Clinical holds, information requests, and safety reports: when regulatory authority actions reach your site
5.4Non-U.S. regulatory interactions: EMA, national competent authorities, and the RC's coordination role in global trials
VIStakeholder communication in the submission process3 lessons · knowledge check
6.1PI engagement: securing signatures, communicating regulatory obligations, and managing investigators who view regulatory work as someone else's problem
6.2Sponsor and CRA communication: approval notifications, document routing, and the regulatory timeline as a shared accountability
6.3IRB correspondence management: responding to stipulations, routing modification requests, and maintaining the regulatory narrative across submissions
VIIStudy closure and final regulatory notifications3 lessons · knowledge check
7.1The regulatory close-out checklist: what the IRB needs, what the sponsor needs, what the institution needs
7.2Final study report preparation: enrollment, deviations, adverse events, and study outcomes
7.3Managing parallel closures: when multiple studies end in the same quarter
VIIIPortfolio timeline management in the submission context4 lessons · knowledge check
8.1Building the regulatory calendar: mapping every submission deadline across the portfolio
8.2Conflict identification and resolution: when three continuing reviews and two initial submissions are due the same week
8.3Forecasting and capacity planning: anticipating the regulatory workload 90 days out
8.4The submission timeline as a management tool: using it to communicate resource needs to site leadership
Final Exam: Regulatory Submissions & Stakeholder Management55 questions · 80% to pass · 75 minutes · up to 3 attempts
Read three lessonsbefore you enroll.
Each is open now, exactly as enrolled learners read them. Every lesson in the course is written, cited and narrated the same way.
Module I · Lesson 120 min
From single-study submission to submission pipeline management: the RC's operational shift
Defines the operational shift from per-study submission execution to portfolio-level pipeline management, identifying five pipeline-only capabilities and the failure modes that emerge without them.
Continuing review timelines and the cost of a regulatory lapse
Quantifies the operational and regulatory consequences of a continuing review lapse and establishes the early-warning infrastructure that prevents it across a multi-study portfolio.
FDA Form 1572: what it commits your investigator to, and when it needs updating
Analyzes the commitments embedded in FDA Form 1572 per 21 CFR 312.53, designs portfolio-level 1572 maintenance tracking, and evaluates the regulatory risk of outdated investigator information across IND studies.
Each point links back to its section of the guideline.
Narrated end to end
Listen when you can’t sit down to read.
Saves your place
Pick up exactly where you stopped.
Studied as part ofthe Regulatory Coordinator track.
Regulatory Submissions & Stakeholder Management is the second of seven courses in the Regulatory Coordinator track. It is not sold on its own: one enrollment opens every course, every final exam and the certificate.
Regulatory Coordinator
Portfolio-level regulatory operations training for clinical research sites
Courses
7
Lessons
180
Study time
~67 h
Pass every final exam and your credential is issued, with the printable certificate included.
$179 USDOne payment for the whole track. Access does not expire.
How it is enrolled in, what the exam asks, and what you can read first.
Can I take this course on its own?
Not separately. Regulatory Submissions & Stakeholder Management is the second course in the Regulatory Coordinator track, and the track is enrolled in as one: all seven courses, every final exam and the certificate, for one payment of $179 USD.
What does the final exam ask?
Fifty-five questions in 75 minutes, with 80% needed to pass, and up to three attempts. Each module also closes with a knowledge check.
Can I read any of it before I enroll?
Yes. Three lessons are open now: “From single-study submission to submission pipeline management: the RC's operational shift”, “Continuing review timelines and the cost of a regulatory lapse” and “FDA Form 1572: what it commits your investigator to, and when it needs updating”.
Is it aligned to ICH E6(R3)?
Yes. The course works from ICH E6(R3).
Does course access expire?
No. Access is yours for good. The Regulatory Coordinator credential the track awards is valid for two years.
Study Regulatory Submissions & Stakeholder Management,within the Regulatory Coordinator track.
One enrollment opens all seven courses, every final exam and the certificate. Course access does not expire.
Not separately. Regulatory Submissions & Stakeholder Management is the second course in the Regulatory Coordinator track, and the track is enrolled in as one: all seven courses, every final exam and the certificate, for one payment of $179 USD.
Can I read any of it before I enroll?
Yes. Three lessons are open now: “From single-study submission to submission pipeline management: the RC's operational shift”, “Continuing review timelines and the cost of a regulatory lapse” and “FDA Form 1572: what it commits your investigator to, and when it needs updating”.
Read three lessonsbefore you enroll.
Each is open now, exactly as enrolled learners read them. Every lesson in the course is written, cited and narrated the same way.
Module I · Lesson 120 min
From single-study submission to submission pipeline management: the RC's operational shift
Defines the operational shift from per-study submission execution to portfolio-level pipeline management, identifying five pipeline-only capabilities and the failure modes that emerge without them.
Continuing review timelines and the cost of a regulatory lapse
Quantifies the operational and regulatory consequences of a continuing review lapse and establishes the early-warning infrastructure that prevents it across a multi-study portfolio.
FDA Form 1572: what it commits your investigator to, and when it needs updating
Analyzes the commitments embedded in FDA Form 1572 per 21 CFR 312.53, designs portfolio-level 1572 maintenance tracking, and evaluates the regulatory risk of outdated investigator information across IND studies.